From the Journals

Adding vasopressin in distributive shock may cut AF risk


 

FROM JAMA


The current Surviving Sepsis guidelines suggest either adding vasopressin to norepinephrine to help raise mean arterial pressure to target or adding vasopressin to decrease the dosage of norepinephrine. Those are considered weak recommendations based on moderate quality of evidence, Dr. McIntyre and colleagues noted in their report.

Authors of the study reported disclosures related to Tenax Therapeutics, Orion Pharma, Ferring Pharmaceuticals, GlaxoSmithKline, and Bristol-Myers Squibb, among other entities.

SOURCE: McIntyre WF et al. JAMA. 2018;319(18):1889-900.

Pages

Recommended Reading

Late-Breaking Science preview: Sunday, Nov. 12
MDedge Hematology and Oncology
Direct oral anticoagulants okay during AF device placement
MDedge Hematology and Oncology
VIDEO: Anticoagulant underprescribing common, jeopardizing atrial fib patients
MDedge Hematology and Oncology
Surgical LAA occlusion tops anticoagulation for AF thromboprotection
MDedge Hematology and Oncology
LAA occlusion boosts anticoagulants’ protection
MDedge Hematology and Oncology
Beware of polypharmacy in patients taking warfarin
MDedge Hematology and Oncology
VIDEO: Andexanet alfa effectively reverses factor Xa anticoagulant
MDedge Hematology and Oncology
MDedge Daily News: Time to let more pregnant women into drug trials?
MDedge Hematology and Oncology
MDedge Daily News: Which diabetes drug boosts survival best?
MDedge Hematology and Oncology
First reversal agent for apixaban and rivaroxaban gets fast-track approval
MDedge Hematology and Oncology